If you have been reading about GW501516 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-17. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
== Season 9 (2023) == In season 9, host John Henson portrays the heir of the abandoned "Henson & Sons Carnival" where he presents baking challenges themed around the grisly deaths of his circus performer relatives.
On March 20, 1976, Marrow's high school girlfriend Adrienne gave birth to their daughter LeTesha Marrow, and they continued attending high school while raising her. While filming Breakin' in 1984, he met his second girlfriend Darlene Ortiz, who was at the club where the film was shot. They began a relationship and Ortiz was featured on the covers of Rhyme Pays and Power. Ice-T and Ortiz had a son, Ice Tracy Marrow Jr., on November 23, 1991; Ice Marrow, aka "Little Ice", became a backing vocalist with Body Count in time for the recording of their album Carnivore. Ice-T married swimsuit model Coco Austin in January 2002. In celebration of their impending ninth wedding anniversary, the couple renewed their wedding vows on June 4, 2011. As of 2006, they owned a penthouse apartment in North Bergen, New Jersey. In 2012, they were building a five-bedroom house in Edgewater, New Jersey, that was expected to be completed by the end of the year. In 2015, the couple had their first child together, a daughter. Ice-T has stated on numerous occasions that he is a teetotaler, and lives a straight edge lifestyle. He is a long time practitioner of Brazilian Jiu-Jitsu and boxing, and is a big fan of the UFC.
=== Alpine Golf Course shareholders === Alpine Golf Course, located in Khlong Luang District, Pathum Thani Province, was originally owned by Nueam Chamnarnchatsakda, who donated the land to Wat Thammikaram Worawihan in 1969. In 1990, the land—designated as Sangha property (monastic land)—was sold and transferred to Alpine Real Estate Co., Ltd. and Alpine Golf and Sports Club Co., Ltd. The shareholders of these companies included Uraiwan Thienthong, wife of Sanoh Thienthong (Deputy Minister of the Interior at the time), and Chuchip Hansawat (Deputy Minister of Commerce). In 1997, the land was sold to Potjaman Shinawatra, wife of then-Prime Minister Thaksin Shinawatra, and Yongyuth Wichaidit, Deputy Permanent Secretary of the Ministry of Interior. A subsequent order revoked the Land Department's cancellation of the title deed for the land due to its Sangha property status. Later, in 2012, Thailand's National Anti-Corruption Commission (NACC) ruled that Yongyuth had acted dishonestly in the case. In 2019, both the Court of First Instance and the Court of Appeal sentenced Yongyuth to two years in prison for corrupt conduct. Currently, the two companies are owned by Potjaman and her three children, including Paetongtarn Shinawatra.
Sources: en.wikipedia.org
=== End of the party === The passing of the Enabling Act did not, as Kaas had suggested, prevent the Centre Party's demise. As promised during the negotiations, a working committee chaired by Hitler and Kaas was supposed to inform about further legislative measures. However, it met only three times (31 March, 2 and 7 April) without any major impact. At that time, the Centre Party was weakened by massive defections by party members. Loyal party members, in particular civil servants, and other Catholic organisations were subject to increasing reprisals, despite Hitler's previous guarantees. The party was also hurt by a declaration of the German bishops that, while maintaining their opposition to Nazi ideology, modified the ban on cooperation with the new authorities. The issue of the concordat prolonged Kaas's stay in Rome, leaving the party without an effective chairman: On 5 May Kaas finally resigned from his post and the party now elected Brüning as his successor. The party adopted a tempered version of the leadership principle; pro-Centre papers now declared that the party's members, or "retinue", would fully submit itself to Brüning. It was not enough, however, to relieve the growing pressure that it and other parties faced in the wake of the process of Gleichschaltung. Prominent members were frequently arrested and beaten, and pro-Centre civil servants were fired. As the summer of 1933 wore on, several government officials—including Papen—demanded that the Centre either dissolve or be closed down by the government.
=== Disease === Chronic Granulomatous Disease is an inherited disease of human neutrophils, wherein NOX2 is defective. Phagocytosis may still occur, but without proper functioning NOX2, there is no superoxide production, and therefore no respiratory burst. The bacterial infection is not cleared.
During 2012, approximately 5.9 metric tons of illicit amphetamine were seized within EU member states; the "street price" of illicit amphetamine within the EU ranged from €6–38 per gram during the same period. Outside Europe, the illicit market for amphetamine is much smaller than the market for methamphetamine and MDMA.
This technology went on to be expanded using fluorinated initiator molecules used within the porous silicon and was described as Nanostructure Initiator Mass Spectrometry (NIMS), it is also known as Nanostructure Imaging Mass Spectrometry (NIMS) because of its expanded application to imaging. In 2005, the Siuzdak lab was engaged in identifying dysregulated metabolic peaks from liquid chromatography mass spectrometry data sets, to address the issue retention time alignment they developed the first algorithm that allowed for the nonlinear alignment of metabolomics data called XCMS. From the early 2000s to the present, the Siuzdak lab created and has been expanding the tandem mass spectrometry database known as METLIN. METLIN is made up solely of experimental data generated from high resolution tandem mass spectrometry instrumentation, all of the data is derived from molecular standards. METLIN (as of May 2025) has over 960,000 molecular standards with experimental tandem mass spectrometry data. METLIN is unique with respect to its size, as other databases are over an order of magnitude smaller, and it is also unique because all of METLIN's tandem mass spectrometry data has been systematically generated at multiple collision energies and in positive and negative ionization modes. In 2020, the Siuzdak lab building off their work with Xavi Domingo and METLIN, developed Enhanced In-Source Fragmentation/Annotation (EISA) to facilitate the fragmentation, identification, and quantification (via Q-MRM) of molecules without the use of tandem mass spectrometry.
Sources: en.wikipedia.org
Cadmium is a chemical element; it has symbol Cd and atomic number 48. This soft, silvery-white metal is chemically similar to the two other stable metals in group 12, zinc and mercury. Like zinc, it demonstrates oxidation state +2 in most of its compounds, and like mercury, it has a lower melting point than the transition metals in groups 3 through 11. Cadmium and its congeners in group 12 are often not considered transition metals, in that they do not have partly filled d or f electron shells in the elemental or common oxidation states. The average concentration of cadmium in Earth's crust is between 0.1 and 0.5 parts per million (ppm). It was discovered in 1817 simultaneously by Stromeyer and Hermann, both in Germany, as an impurity in zinc carbonate. Cadmium occurs as a minor component in most zinc ores and is a byproduct of zinc production. It was used for a long time in the 1900s as a corrosion-resistant plating on steel, and cadmium compounds are used as red, orange, and yellow pigments, to color glass, and to stabilize plastic. Cadmium's use is generally decreasing because it is toxic, and nickel–cadmium batteries have been replaced with nickel–metal hydride and lithium-ion batteries. Because it is a neutron poison, cadmium is also used as a component of control rods in nuclear fission reactors. One of its few new uses is in cadmium telluride solar panels. Although cadmium has no known biological function in most organisms, a cadmium-dependent carbonic anhydrase has been found in certain diatoms.
=== U.S. relations with Marshall Islands === Section 177 of the 1983 Compact of Free Association between the governments of the United States and the Marshall Islands establishes a process for Marshallese to make a claim against the United States government as a result of damage and injury caused by nuclear testing. That same year, an agreement was signed to implement Section 177, which established a US$150 million trust fund. The fund was intended to generate US$18 million a year, which would be payable to claimants on an agreed-upon schedule. If the US$18 million a year generated by the fund was not enough to cover claims, the principal of the fund could be used. A Marshall Islands Nuclear Claims Tribunal was established to adjudicate claims. In 2000, the tribunal made a compensation award to the people of Enewetak consisting of US$107.8 million for environmental restoration; US$244 million in damages to cover economic losses caused by loss of access and use of the atoll; and US$34 million for hardship and suffering. In addition, as of the end of 2008, another US$96.658 million in individual damage awards were made. Only US$73.526 million of the individual claims award has been paid, however, and no new awards were made between the end of 2008 and May 2010. Due to stock market losses, payments rates that have outstripped fund income, and other issues, the fund was nearly exhausted, as of May 2010, and unable to make any additional awards or payments.
== Interactions == Concurrent use with other triptans or ergot-containing medications (e.g., ergotamine, dihydroergotamine) within 24 hours can result in additive vasoconstriction. Increased systemic exposure to sumatriptan can occur if used within 2 weeks after a monoamine oxidase inhibitor (MAOI). Cases of serotonin syndrome have been reported with co-administration of triptans and serotonin reuptake inhibitors.
=== Extraction for treatment === Extracted growth hormone was used since the late 1950s until the late 1980s when its use was replaced by recombinant GH. In the late 1950s, Maurice Raben purified enough GH from human pituitary glands to successfully treat a GH-deficient boy. A few endocrinologists began to help parents of severely GH-deficient children to make arrangements with local pathologists to collect human pituitary glands after removal at autopsy. Parents would then contract with a biochemist to purify enough growth hormone to treat their child. Few families could manage such a complicated undertaking. In 1960, the National Pituitary Agency was formed as a branch of the U.S. National Institutes of Health. The purpose of this agency was to supervise the collection of human pituitary glands when autopsies were performed, arrange for large-scale extraction and purification of GH, and distribute it to a limited number of pediatric endocrinologists for treating GH-deficient children under research protocols. Canada, UK, Australia, New Zealand, France, Israel, and other countries establish similar government-sponsored agencies to collect pituitaries, purify GH, and distribute it for treatment of severely GH-deficient children. Supplies of this "cadaver growth hormone" were limited, and only the most severely deficient children were treated. From 1963 to 1985 about 7,700 children in the U.S. and 27,000 children worldwide were given GH extracted from human pituitary glands to treat severe GH deficiency.
=== Aminopyridines === 2-Aminopyridine, 3-aminopyridine, and 4-aminopyridine are colorless solids. The more common 2-derivative is obtained by treating pyridine with sodium amide, the so-called Chichibabin reaction. It is a precursor to piroxicam, tenoxicam, sulfapyridine, tripelennamine, and other commercial bioactive compounds. The 3- and 4-aminopyridines are produced from the corresponding carboxamides by the Hofmann rearrangement. All three isomers are versatile intermediates via diazotization.
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.